SEC Company Response from Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Nov 5, 2019
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Nov. 5, 2019 · CIK: 0001645469 · Accession: 0001654954-19-012376
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233303
Letter
Blueprint
Monopar Therapeutics Inc.
Skokie Blvd., Suite 350
Wilmette, Illinois 60091
November 5, 2019
VIA EDGAR
US Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re: Monopar Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-233303
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be declared effective at 4:00 p.m., Eastern time, on November 7, 2019 or as soon thereafter as practicable, or such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance.
Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.
Very
truly yours,
Monopar
Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
Blueprint
Monopar Therapeutics Inc.
1000
Skokie Blvd., Suite 350
Wilmette,
Illinois 60091
November
5, 2019
VIA EDGAR
US
Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, NE
Washington,
DC 20549
Re:
Monopar Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-233303
Ladies
and Gentlemen:
Pursuant to Rule
461 under the Securities Act of 1933, as amended, Monopar
Therapeutics Inc. (the “Company”) hereby respectfully
requests that the above-referenced Registration Statement be
declared effective at 4:00 p.m., Eastern time, on November 7, 2019
or as soon thereafter as practicable, or such later time as the
Company or its counsel may orally request via telephone call to the
staff of the Division of Corporation Finance.
Please
contact John Harrington of Baker & Hostetler LLP at (216)
861-6697 with any questions regarding the foregoing and to confirm
the effectiveness of the Registration Statement.
Very
truly yours,
Monopar
Therapeutics Inc.
By:
/s/
Chandler D.
Robinson
Chandler D.
Robinson
Chief Executive
Officer